Cara Therapeutics (CARA)
(Delayed Data from NSDQ)
$0.72 USD
-0.04 (-5.85%)
Updated May 10, 2024 04:00 PM ET
After-Market: $0.71 -0.01 (-0.78%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Earnings News For CARA
-
Cara: Q4 Earnings Snapshot
-
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
-
Cara: Q3 Earnings Snapshot
-
Cara Therapeutics Reports Third Quarter 2023 Financial Results
-
Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to Decline
-
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
-
Cara: Q2 Earnings Snapshot
-
Cara Therapeutics Reports Second Quarter 2023 Financial Results
-
Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates
-
Cara: Q1 Earnings Snapshot
-
Cara Therapeutics Reports First Quarter 2023 Financial Results
-
Cara: Q4 Earnings Snapshot
-
Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates
-
Will Cara Therapeutics (CARA) Report Negative Earnings Next Week? What You Should Know
-
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
-
Cara: Q3 Earnings Snapshot
-
Cara Therapeutics Reports Third Quarter 2022 Financial Results
-
Cara Therapeutics (CARA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
-
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
-
Cara: Q2 Earnings Snapshot
-
Cara Therapeutics Reports Second Quarter 2022 Financial Results
-
Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates
-
Cara Therapeutics (CARA) Reports Q4 Loss, Lags Revenue Estimates
-
Earnings Preview: Cara Therapeutics (CARA) Q4 Earnings Expected to Decline
-
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates